# A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

> **NCT00843492** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1351 (actual)

## Conditions studied

- Thrombosis, Venous

## Interventions

- **DRUG:** Fondaparinux sodium
- **DRUG:** Nadroparin

## Key facts

- **NCT ID:** NCT00843492
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-06
- **Target enrollment:** 1351 (ACTUAL)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843492, "A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00843492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*